Version June 2024
| Patients with cancer are a special population that should be largely exempt from restrictive regulations intended to restrict access or limit doses. |
| Providers should have a choice of sources and materials for education in opioid prescribing. |
| Patients with cancer and survivors of cancer should not be subject to arbitrary prescription limits that artificially limit access to medically necessary treatment. |
| Patient education on the correct medical use of opioids is best provided by a health care professional with the addition of supplementary materials, as appropriate. |
| Individual state prescription-drug monitoring programs should be accessible through a single portal or interoperable in a way that is seamless to the user. |
| ASCO supports efforts to develop abuse-deterrent formulations as one approach to mitigating abuse but notes that most prescription drug abuse and overdose occur via the oral route. |
| Individuals with an opioid-related disorder should have rapid access to appropriate assessment, diagnosis, and treatment, regardless of the patient’s payer or geographic setting. |
| Patients should have increased access to naloxone, a lifesaving medication, in cases of opioid overdose by patients, caregivers, and first responders. |
| To decrease the availability of unused or unwanted opioid drugs, authorized prescription "Take Back" collection sites should be readily available to patients. |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
